Excerpts provided by Lawrence Jones, Ph.D
Photo Courtesy Baltimore Sun May 30, 2019: Dr. Kenneth Kinzler, left, and Dr. Bert Vogelstein are among researchers at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center who have worked to develop the test. (Lloyd Fox / Baltimore Sun 2014)
Hub (Jun 3, 2019) reports that Thrive Earlier Detection Corporation, launched last month with $110 million in Series A funding. “The $110 million raised by the medical firm represents the largest-ever Series A, or early round, investment in a Hopkins technology by a licensee in Hopkins’ history, the university said”(Mirabella, May 30, 2019). The company founded by Johns Hopkins Researchers Dr. Bert Vogelstein, Dr. Kenneth Kinzler, and Dr. Nickolas Papadopoulos.
The test, CancerSEEK, is a liquid biopsy test designed to detect multiple cancer types at earlier stages of the disease. Funding by Third Rock Ventures, a Boston-based health care venture firm, led the financing. “Thrive will have offices in Massachusetts and Baltimore and will conduct its research and development at the 1812 Ashland building, part of Johns Hopkins’ innovation hub on the East Baltimore campus.” The company will initially have 25 employees and occupy 18,000 square feet of office space in Baltimore. Thrive also plans to draw upon demographic and phenotypic information, to create a learning loop that fine-tunes test performance and expands the number of people who can benefit from earlier cancer screening over time.
More to read: https://hub.jhu.edu/2019/06/03/cancerseek-blood-test/
Malone, A. (Jun 3, 2019). Early Cancer Detection Technology Receives Record Venture Investment. Hub. https://hub.jhu.edu/2019/06/03/cancerseek-blood-test/
Mirabella,L. (May 30, 2019).Baltimore Firm Raises $110 million to Bring Johns Hopkins’ Cancer-Detecting Blood Test to Market.Baltimore Sun. https://www.baltimoresun.com/health/bs-bz-company-develops-hopkins-cancer-blood-test-20190529-story.html